Clinical trials: Abiraterone Acetate, open to volunteers
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have…
- Trial name
- TALENT (NCT06844383)
- Testing
- Talazoparib with enzalutamide, Talazoparib
- Where
- 8 sites in United States
- Volunteers
- 126 people
- Sponsor
- Prostate Cancer Clinical Trials Consortium
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle.
- Conditions
- Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
- Trial name
- NCT04729114
- Testing
- PRL-02 injection, prednisone, dexamethasone
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer Metastatic, Prostate Cancer
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone.
- Trial name
- APRE (NCT03833921)
- Testing
- Abiraterone Acetate, Prednisone
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Martha Mims
Metastatic Castration Resistant Prostate Cancer
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or…
- Trial name
- Himalayas-1 (NCT07723248)
- Testing
- Rinzimetostat, Darolutamide, Enzalutamide
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- ORIC Pharmaceuticals
Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer)
Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC
Acetate abiraterone tablets (II) is a modified new drug launched in China, prepared using nanocrystal technology and supplemented with SNAC as an absorption enhancer, working together to promote the gastrointestinal absorption of…
- Trial name
- mCRPC (NCT06768255)
- Testing
- Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT, Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Ding-Wei Ye
Metastatic Castration-resistant Prostate Cancer
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
- Trial name
- NCT07213674
- Testing
- Xaluritamig, Abiraterone acetate, Docetaxel
- Where
- 159 sites in United States, Australia and 16 more
- Volunteers
- 750 people
- Sponsor
- Amgen
The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
This study is a single-arm, multicenter, phase II exploratory trial. The purpose is to explore the efficacy and safety of Darxicilib in combination with Abiraterone Acetate for the treatment of subjects with metastatic…
- Trial name
- NCT06500247
- Testing
- Dalpicilib, Abiraterone Acetate (II), Androgen Deprivation Therapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Qilu Hospital of Shandong University
Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
This phase III/IV trial compares the impact of leuprolide and abiraterone acetate (AA) versus relugolix and AA on the heart in hormone-naive patients with advanced prostate cancer receiving pelvic radiation therapy.
- Conditions
- Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT06650579
- Testing
- Abiraterone Acetate, Bicalutamide, Biospecimen Collection
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Emory University
Metastatic Cancer, Neoplasm, Prostate
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC.
- Conditions
- Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
- Trial name
- NCT05422911
- Testing
- Abiraterone acetate, Apalutamide, Enzalutamide
- Where
- 12 sites in United States
- Volunteers
- 192 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Prostate Cancer
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine…
- Trial name
- NCT06689163
- Testing
- HRS-1167 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
- Trial name
- NCT07104617
- Testing
- TY-302, Abiraptor
- Where
- China
- Volunteers
- 48 people
- Sponsor
- TYK Medicines, Inc
High-Risk Prostate Cancer
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk…
- Trial name
- SNARE (NCT05593497)
- Testing
- Capivasertib, abiraterone acetate
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development
High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
This study was to evaluate the safety and efficacy of dalcilide tablets in combination with AA-P in the treatment of subjects with high tumor burden mHSPC and to determine the second stage starting dose and progression-free…
- Trial name
- NCT06099990
- Testing
- dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
- Volunteers
- 660 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC
This study is an open label, single arm, multicenter clinical trial. The aim of this study is to evaluate the efficacy, safety, and quality of life of radiotherapy combined with Fuzuloparib and Abiraterone Acetate Tablets（Ⅱ） as…
- Trial name
- PARTOM (NCT06971211)
- Testing
- Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jianbin Bi
MCRPC
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating the efficacy and safety of HC-1119 soft capsules versus placebo in mCRPC patients who have failed or become intolerant to the…
- Trial name
- NCT03851640
- Testing
- HC-1119
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Prostate Cancer Metastatic
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall…
- Trial name
- OMAHA-003 (NCT06136624)
- Testing
- Opevesostat, Abiraterone acetate, Enzalutamide
- Where
- 288 sites in United States, Argentina and 34 more
- Volunteers
- 1,310 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate…
- Trial name
- NCT06136650
- Testing
- Opevesostat, Dexamethasone, Fludrocortisone acetate
- Where
- 330 sites in United States, Australia and 37 more
- Volunteers
- 1,314 people
- Sponsor
- Merck Sharp & Dohme LLC